International Clinical Psychopharmacology · 2000 · 37 citations · 0 references
PharmacyPharmacotherapyPsychiatryNeuropharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyDopaminergic PharmacologyNeuropsychiatric PharmacotherapySchizophrenia PharmacotherapyAntipsychotic ActionAntipsychotic-induced Tardive DyskinesiaAtypical Antipsychotic TreatmentD2-like Dopamine ReceptorsDopamine D2-like ReceptorsQuetiapine TherapySingle-case Study DesignTardive Dyskinesia Treatment
In a single inpatient case study, a schizophrenic patient with tardive dyskinesia after prolonged treatment with typical neuroleptics was treated with the new atypical neuroleptic quetiapine, a dibenzothiazepin-derivative. Within 2 weeks of treatment with quetiapine, symptoms of tardive dyskinesia improved; 10 weeks after starting treatment tardive dyskinesia stopped completely. Over the same period, dopamine D2 receptor occupancy decreased substantially, as measured by IBZM-SPECT after 14 and 77 days of treatment.